Jennewein Biotechnologie GmbH enforces its patents in the field of human milk oligosaccharides against Nestlé in Germany

January 13, 2020 - 09:19
Jennewein Biotechnologie GmbH enforces its patents in the field of human milk oligosaccharides against Nestlé in Germany

RHEINBREITBACH, GERMANY - Newsaktuell - 13 January 2020 - Jennewein Biotechnologie GmbH filed a patent infringement suit with the regional court in Mannheim on January 09, 2020 against Nestlé Nutrition GmbH and its holding company Nestlé Deutschland AG. Nestlé offers its infant formula Beba Supreme which contains two human milk oligosaccharides -- unique saccharides naturally occurring in human breast milk only -- for sale in Germany. Pursuant to the findings of Jennewein Biotechnologie, Nestlé uses human milk oligosaccharides for the manufacturing of its infant formula that are produced by a process being protected - among other IP rights - by European Patents EP 2 896 628 and EP 3 131 912 (start of protection: January 22, 2020) which are thus infringed by Nestlé.


As Nestlé offers its infant food containing human milk oligosaccharides not just in Germany, Jennewein currently investigates measures against the assumed infringement of its corresponding foreign patents by the manufacturing of products such as Illuma, SMA, NAN and Gerber Good Start.

The issuer is solely responsible for the content of this announcement

About HMOs:

Human milk oligosaccharides (HMOs) arecomplex sugar molecules that are only present in  breast milk. Excluding water, they are thethird most abundant constituent of human milk after fats and lactose. More than200 structurally different HMOs have been identified. The most abundant HMO is2′-fucosyllactose, which is produced by about 80% of all       lactating mothers at concentrations ofup to 3 g/L. Scientific studies have shown that HMOs, and 2′‑fucosyllactose inparticular, have a positive impact on infant health and development. HMOs areprebiotics, i.e. they specifically promote the growth of beneficial microorganisms,and at the same time they inhibit the growth of pathogens by directly andindirectly preventing colonisation. Jennewein Biotechnologie launched2′-fucosyllactose onto the global baby food market in 2015, and several infantmilk formulas around the world now contain 2′-fucosyllactose (e.g. AbbottSimilac).

About Jennewein Biotechnologie:

JenneweinBiotechnologie is a leading international industrial biotechnology company witha range of products in the field of complex oligosaccharides (HMOs) and raremonosaccharides. The company manufactures an extensive portfolio ofinnovative HMO products, such as 2′‑fucosyllactose, 3-fucosyllactose and lacto-N-tetraose.These rare sugars are used in the food industry (particularly infant milkformulas), the pharmaceutical industry, and the cosmetic industry. Themanufacturing process involves state-of-the-art fermentation techniques. In2015, the US Food and Drug Administration (FDA) granted JenneweinBiotechnologie a license to market 2′-fucosyllactose in the USA. This wasfollowed in 2017 by The European Food Safety Authority (EFSA) under the NovelFood Regulation.